BIO 2015 Dispatches: Data Transparency Initiatives Could Deter Industry Investment, Attorney Says
This article was originally published in The Pink Sheet Daily
Covington partner Richard Kingham says early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But EMA's Hans-Georg Eichler says investors should welcome the initiatives because they will bring greater efficiency to drug development.
Register for our free email digests: